Development of an antisense oligonucleotides-based therapy for mucolipidosis type II α/β: in vivo studies
Introduction: The RNA molecule has become an increasingly promising target for the therapy of various diseases. Mucolipidosis type II α/β (ML II α/β) is one of the most severe Lysosomal Storage Disorders and is caused by the deficiency of the enzyme GlcNAc-1- phosphotransferase. This enzyme is respo...
Autor principal: | |
---|---|
Outros Autores: | , , , , , , |
Formato: | conferenceObject |
Idioma: | eng |
Publicado em: |
2022
|
Assuntos: | |
Texto completo: | http://hdl.handle.net/10400.18/8191 |
País: | Portugal |
Oai: | oai:repositorio.insa.pt:10400.18/8191 |